Systemic Lupus Erythematosus | Unmet Need | US/EU | 2022

Systemic lupus erythematosus (SLE) is an autoimmune disease that can affect different organ systems of the body and manifest in a wide range of clinical symptoms, from general fatigue to serious renal and CNS manifestations. Most drugs used to treat SLE are older, generically available, and off-label. To date, GlaxoSmithKline’s Benlysta and AstraZeneca’s Saphnelo—both viewed by many physicians as only modestly effective—are the only drugs approved for moderate to severe SLE (excluding severe active renal and severe active CNS manifestations). Thus, unmet need remains high in the moderate to severe subpopulation, leaving significant commercial opportunity for novel SLE therapies that are more efficacious than Benlysta and Saphnelo.

QUESTIONS ANSWERED

• What are the treatment drivers and goals in moderate to severe SLE (excluding severe active renal and severe active CNS manifestations)?
• What drug attributes are key influencers, which have limited impact, and which are hidden opportunities?
• How do current therapies perform on key treatment drivers and goals for moderate to severe SLE (excluding severe active renal and severe active CNS manifestations)?
• What are the prevailing areas of unmet need and opportunity in the treatment of moderate to severe SLE (excluding severe active renal and severe active CNS manifestations)?
• What trade-offs across different clinical attributes and price are acceptable to rheumatologists for a hypothetical new drug for moderate to severe SLE (excluding severe active renal and severe active CNS manifestations)?

PRODUCT DESCRIPTION

Provides quantitative insight into U.S. and European physician perceptions of key treatment drivers and goals and the current level of unmet need for a specific disease. Commercial opportunities are analyzed, and the extent to which emerging therapies may capitalize on these opportunities is evaluated.

Markets covered: United States, United Kingdom, France, Germany

Primary research: Survey of 60 U.S. and 30 European rheumatologists fielded in January 2022

Key companies: GlaxoSmithKline, Bristol Myers Squibb, Roche, AstraZeneca, Janssen, Eli Lilly

Key drugs: Benlysta, Rituxan / MabThera, Saphnelo, CellCept, hydroxychloroquine, methotrexate, azathioprine